



Learning objectives

- Understand the extent of the opioid epidemic nationally.
- Understand drug trends and current data in Wisconsin.
- Understand the signs and symptoms of opioid misuse and abuse.
- Understand medication-assisted treatment (MAT) and its application in Wisconsin.
- Understand the Department of Health Services response to Wisconsin's opioid crisis.


2









Oxycodone consumption, 2016



















Three waves of opioid overdose deaths


- 1. Prescription pain relievers
- 2. Heroin
- 3. Fentanyl











































Condition	Percentage (Rounded)
Non-ortho surgery pain	18%
Orthopedic surgery pain	17%
Back pain	15%
Short-term injury pain	10%
Dental	9%
Joint pain	8%
Long-term injury pain	6%
Other	5%











Definition


Neonatal abstinence syndrome (NAS) is a group of conditions caused when a baby withdraws from drugs he/she was exposed to in the womb before birth.

Signs and symptoms

- Breathing problemsDiarrhea
- Fever
- Fussiness, high-pitched cry
 Poor feeding

- SeizuresStuffy nose or sneezing
- **D** Tremors

25



26



Hepatitis C


- Hepatitis C is a serious liver infection caused by the hepatitis C virus.
- Hepatitis C is a leading cause of liver cancer, a leading reason for liver transplantation, and a leading infectious cause of death.
- Today most people acquire hepatitis C through injection drug use with shared, unsterilized equipment.

28


Hepatitis C trends


- Because most people newly infected with hepatitis
 C do not have symptoms until many years after infection, testing is required to make a diagnosis and diagnoses of hepatitis C are underreported.
- DHS monitors trends in new hepatitis C infections by monitoring trends in acute cases and cases among young adults.
- In the past decade, new hepatitis C infections have increased substantially as injection drug use has increased.


29


































Other health risks

- □ HIV
- **D** Osteomyelitis
- Sexually transmitted infections
 Septic arthritis
- □ Tuberculosis
- **D** Thrombophlebitis

37

Staying safe and harm reduction

38

Fentanyl test strips

- **□** Given to injection drug users
- **D** Partner: AIDS Resource Center of Wisconsin
- Milwaukee pilot: January-April 2019
- **D** Statewide as of May 2019
- Three strips to each individual on each visit (January-May)



Fentanyl test strips (Jan.-Sept. 2019)

1,079 individuals received strips271 individuals reported results on 725 tests

40

Fentanyl test strips (Jan.-Sept. 2019)

Type of drug tested

Cocaine: 6

- Negative: 1
- Positive: 5

Heroin: 658

- Negative: 196
- Positive: 459
 Dida(humanla (no lines))
- Didn't work (no lines): 3

41

Fentanyl test strips (Jan.-Sept. 2019) Type of drug tested Methamphetamine: 36 • Negative: 11 • Positive: 25 Combination/Other: 22 • Negative: 7 • Positive: 15

Fentanyl Test Strips (Jan.-Sept. 2019)

Time test conducted Before using: 637 Negative: 207 Positive: 430

- Positive: 430 ■ After using: 75
- □ Unknown: 13

43

Fentanyl Test Strips (JanSept. 2019) Pushed Pushed Sniffed Threw Used Use the Used								
	plunger more slowly than usual	plunger partway to feel potency	instead of inject	away drug	less than planned	same as planned	with a friend	
Negative (tested before using)	30 (14.5%)	8 (3.8%)	0	1 (0.4%)	7 (3.3%)	132 (63.8%)	100 (48.3%)	
Positive (tested before using)	181 (42.1%)	130 (30.2%)	5 (1.1%)	33 (7.6%)	235 (54.7%)	104 (24.2%)	253 (58.8%)	
Tested after using	5 (6.7%)	5 (6.7%)	0	2 (3.3%)	6 (8.0%)	49 (65.3%)	31 (41.3%)	

44

Naloxone

- **D** Blocks effects of an opioid overdose
- Restores breathing







Naloxone training and distribution

- AIDS Resource Center of Wisconsin
- NARCAN[®] Direct Program
- Prescription Drug/Opioid Overdose-Related Deaths Prevention Project



Behavioral and physical

- Gudden change in hygieneBlackened fingers/smudges
- Constricted/pinpoint pupils
 Itchy arms/neck/legs
- Loss of appetite/weight
 Wearing long sleeves

49

Behavioral and physical

- Doctor shopping
- Pill bottles
- Shoplifting/stealing

50

Behavioral and physical

- Anxiety
- Isolation
- Nodding off

Environmental

- Missing vent screws
- Burned carpet
- Durned curper
 Torn corners of plastic baggies
 Burnt foil/spoons/tea candle tins

52

Environmental

- Pen parts and straws
- Crushed pills and white powder
- Torn cotton swabs, cut cigarette filters
 Plastic bottle caps

53

Environmental

- **D** Folded receipts, lottery tickets
- Sunglasses case
- Blood spots in sink, bedding, and clothes



Medication-assisted treatment

Provides comprehensive services

Medication

- Counseling
- **D** Case management
- Recovery supports

56

Medication-assisted treatment

- Uses many paths to recovery
- Medical intervention
- Professional treatment
- Mutual support groups
- Peer supports
- Family supports
- Faith supports

Medication-assisted treatment

Food and Drug Administration-approved medications **D** Buprenorphine products

- Methadone
- Naltrexone

58

Buprenorphine products

- Schedule III drugs
- Reduce cravings and withdrawal symptoms
- Available at opioid treatment programs and from approved practitioners




Buprenorphine: Sublocade

- **D** Injected under the skin once per month
- Given to people who have started treatment with an oral form of buprenorphine placed under the tongue or inside the cheek
- Recommended dose is 300 mg per month for the first two months followed by a maintenance dose of 100 mg monthly


61

Buprenorphine waiver

- **D** Waiver is now approved up to 275 patients.
- Practitioners are eligible to obtain the waiver if they have additional credentialing in addiction medicine or addiction psychiatry.
- Practitioners are required to complete a Substance Abuse and Mental Health Services Administration reporting form each year.
- Practitioners now include clinical nurse specialist, certified registered nurse anesthetist, and certified nurse midwife.









Approved practitioners in Wisconsin

- **D** Total with a limit of 30: 810
- **D** Total with a limit of 100: 210
- **D** Total with a limit of 275: 66

D This equates to 63,450 treatment slots.

- September 2019

65


Methadone

- Schedule II drug
- **D** Suppresses withdrawal symptoms and cravings

Naltrexone

- **u** It is administered once a month to prevent relapse to opioid dependence after detox.
- **D** Patient must stop all opioids 7-10 days prior to injection.

67









Opioid treatment programs

- Specially licensed centers
- May provide all three forms of Food and Drug Administration-approved medications for opioid use disorders
- \blacksquare 21 in Wisconsin, including one that is open 24/7
- Addresses and phone numbers at <u>www.dhs.wisconsin.gov/opioids</u>

70



71







Substance Abuse and Mental Health Services Administration

- **D** Strategic Prevention Framework Partnerships for Success - 2015 (SPF PFS 15)
- Strategic Prevention Framework for Prescription Drugs (SPF Rx)
- Prescription Drug/Opioid Overdose-Related Deaths Prevention Project (WI PDO)
- State Opioid Response (SOR)

74

SPF PFS 15 (Prevention efforts) **a** \$8.2 million over 5 years (Sept. 2015-Aug. 2020) ■ Focus: Prescription drug misuse and abuse among those 12-25 years-old ■ Locations/counties: Ashland Vilas Oneida Columbia Kenosha Dane Marinette Douglas Menominee Eau Claire Milwaukee

Rock

- Florence
- Forest

SPF PFS 15 (Prevention efforts)

Strategies

- Provide training and support for professionals
 Implement public awareness campaign related to
- opioid use and misuse
 Promote medication security, collection, and disposal

76

SPF PFS 15 (Prevention efforts)

- Alliance for Wisconsin Youth regional prevention centers are funding one coalition to implement these strategies in each of the 14 high-need counties.
- **D** The coalitions began their implementation efforts on October 1, 2016.

77

SPF Rx (Prevention efforts)

- **□** \$1.8 million over 5 years (Sept. 2016-Aug. 2021)
- Focus: Raise awareness of the risks of opioids, promote safe prescribing practices, establish system to track misuse trends
- Location/counties:
 - DodgeSauk

SPF Rx (Prevention efforts)

- Provided training, technical assistance, and support through the Alliance for Wisconsin Youth to substance abuse prevention coalitions in both counties.
- Provided professional development opportunities to community members in both counties engaged in substance abuse prevention work.
- Provided Drug Impairment Training for Education Professionals (DITEP) to educators in both counties to aid in recognizing signs and symptoms of impairment due to substance use.

79

WI PDO (Prevention efforts)

- **a** \$5 million over 5 years (Sept. 2016-Aug. 2021)
- Focus: Overdose death prevention, naloxone distribution
- Location/counties:
 - Kenosha (public health department)Sauk (public health department)
 - Waukesha (health and human services department)

80

WI PDO (Prevention efforts)

- Trained staff on best practices
- Hosted trainings for first responders and family members on how to use naloxone, more than 5,900 individuals trained with more than 130 opioid overdoses reversed

SOR (Treatment and recovery efforts)

- \$23,958,666, plus \$6,253,212 one-time supplemental funding (Oct. 2018-Sept. 2020)
- **□** \$11.9 million per year
- Focus: Increase access to medication-assisted treatment, reduce unmet treatment need, reduce opioid-related deaths
- **D** Location/counties: All regions of Wisconsin

82

Current SOR Projects


- Partnership with Alliance for Wisconsin Youth for prevention projects
- Unmet treatment needs
- **D** Expansion of medication-assisted treatment
- **D** Two regional opioid treatment programs
- "ED2Recovery" Program
- Wisconsin Addiction Recovery Helpline
- **D** Workforce development conferences

83

Wisconsin Addiction Recovery Helpline

- 24/7 free, confidential service
- □ Call 211 or visit addictionhelpwi.org
- Referrals to substance use disorder treatment and recovery services
- **•** Help navigating insurance coverage questions







Conferences

- Opioid Forum
- Wisconsin's Opioid Crisis: A Trauma-Informed Response

2020 Opioid Forum May 5-7, 2020 Wisconsin Dells

86

Heroin, Opioid, Prevention, Education (HOPE) Agenda -**State Funded Projects**

Regional treatment centers

- $\ensuremath{\,\square}$ Five programs serving northern Wisconsin
 - HOPE Consortium (opened in 2015)
 Northeast Wisconsin Opioid Treatment Services (opened in 2015)
 - NorthLakes Community Clinic (opened in 2015)
 - Lake Superior Community Health Center (opened in 2018)
 - Ladysmith Alcohol and Drug Recovery Center (opened in 2018)
- Two forms of medication-assisted treatment are offered (buprenorphine products and naltrexone).
- More than 1,700 people have been served.

88



89

Jail-based medication-assisted treatment

- Grants currently awarded to 14 county agencies and one tribal agency.
- Participating inmates receive a dose of an injectable medication that treats opioid use disorder before their release.
- A treatment plan after release that includes counseling and follow-up injections provided in the community is established to ensure success.

Jail-based medication-assisted treatment

Locations/county jails:

- Bayfield
- Brown
- Columbia
- Dane
- Dodge
- Grant
- Kenosha
- Iowa
- Racine Rock Shawano

Manitowoc

- Sheboygan Vilas
- Walworth
- Washington

91

UW Addiction Consultation Provider Hotline

- **D** Support for treatment providers managing patients with addictions
- **D** Free service
- **D** Call 800-472-0111
- **D** Questions answered by addiction medicine experts at UW-Madison School of Medicine and Public Health and UW Health.

92

Project ECHO

- **D** Training for treatment providers in pharmacotherapy and behavioral interventions for substance use disorders
- **D** Free video conferences held third Friday of every month (12:30-1:30 p.m.)
- □ Case-based learning from specialists in addiction medicine





